February 2, 2015 / 12:26 PM / 3 years ago

Ardelyx kidney drug meets main goal in mid-stage study

Feb 2 (Reuters) - Ardelyx Inc said its experimental drug significantly decreased phosphate levels in chronic kidney disease patients who were on dialysis.

The drug, being co-developed with AstraZeneca PLC, however, led to patients in the mid-stage study having a higher-than-expected rate of diarrhea. (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Savio D'Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below